Revvity (RVTY) Aktievy
Revvity, Inc. tillhandahåller lösningar, teknik och tjänster inom hälsovetenskap. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
RVTY Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Revvity, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$145.73 |
| 52 veckors högsta | US$140.22 |
| 52 veckors lägsta | US$81.22 |
| Beta | 1.09 |
| 1 månads förändring | 25.45% |
| 3 månaders förändring | 45.73% |
| 1 års förändring | 70.66% |
| 3 års förändring | 31.99% |
| 5 års förändring | -21.25% |
| Förändring sedan börsintroduktionen | 4,299.40% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Sep 04
RVTY: AI Screening Demand And Sector Recovery Will Support Future Upside
Analysts have raised their implied fair value for Revvity from about $143 to about $158, reflecting updated views on revenue growth, margins, and P/E assumptions in light of higher Street price targets and commentary on improving demand and AI-driven screening opportunities. Analyst Commentary Recent Street research on Revvity points to a more constructive setup in the stock, with several bullish analysts lifting price targets and highlighting improving demand trends in key end markets.
Uppdatering av berättelse • Aug 20
RVTY: Elevated Multiple And Sector Headwinds Will Challenge 2026 Outlook
Analysts have lifted the fair value estimate for Revvity stock from $90 to $100, pointing to updated price targets in the $115 to $130 range and research that highlights steady sector trends, healthier capital spending, and a higher assumed future P/E multiple, despite more conservative profit margin assumptions. Analyst Commentary on Revvity Recent Street research on Revvity points to a mix of optimism and caution.Recent updates
Uppdatering av berättelse • Sep 04
RVTY: AI Screening Demand And Sector Recovery Will Support Future Upside
Analysts have raised their implied fair value for Revvity from about $143 to about $158, reflecting updated views on revenue growth, margins, and P/E assumptions in light of higher Street price targets and commentary on improving demand and AI-driven screening opportunities. Analyst Commentary Recent Street research on Revvity points to a more constructive setup in the stock, with several bullish analysts lifting price targets and highlighting improving demand trends in key end markets.Uppdatering av berättelse • Aug 20
RVTY: Elevated Multiple And Sector Headwinds Will Challenge 2026 Outlook
Analysts have lifted the fair value estimate for Revvity stock from $90 to $100, pointing to updated price targets in the $115 to $130 range and research that highlights steady sector trends, healthier capital spending, and a higher assumed future P/E multiple, despite more conservative profit margin assumptions. Analyst Commentary on Revvity Recent Street research on Revvity points to a mix of optimism and caution.
Uppdatering av berättelse • Aug 05
RVTY: AI R&D Tools And Sector Backdrop Will Shape Future Earnings Power
Revvity's analyst price targets have shifted higher, with the updated fair value estimate moving from about $117.13 to roughly $121.07 as analysts factor in relatively stronger revenue growth, improved profit margin assumptions, a slightly lower discount rate, and a more moderate future P/E multiple. Analyst Commentary Recent Street research on Revvity gives you a mix of optimism and caution, with several firms fine tuning targets and ratings ahead of upcoming earnings and sector updates.Uppdatering av berättelse • Jul 22
RVTY: AI R&D Tools And Sector Tailwinds Will Support Measured Future Earnings Power
Analysts have raised the aggregated price target for Revvity by about $3.49 per share to $117.13, citing updated views on the broader tools and diagnostics sector and the company’s position within that market. Analyst Commentary Recent research on Revvity presents a mix of optimism and caution, with several firms updating targets and ratings based on sector views, valuation and expectations around execution.Seeking Alpha • Jul 13
Revvity: Overvalued On Sentiment
Summary Revvity, Inc. trades near 52-week highs, buoyed by sector M&A momentum but faces fundamental headwinds. RVTY's projected 2026 revenues are flat over 2025, underperforming the Life Sciences sector's 11% annual growth outlook. Despite management optimism on margin expansion and share buybacks, RVTY trades at a 22% EV/EBIT premium to the sector median. I see RVTY as a near-term short opportunity, with no merger premium expected and limited sales growth post-divestiture. Read the full article on Seeking AlphaUppdatering av berättelse • Jul 07
RVTY: Sector Recovery And AI R&D Platforms Will Drive Future Upside
The analyst price target for Revvity has been revised slightly higher. The fair value estimate has moved from $140.00 to about $142.88 as analysts factor in generally healthy sector demand, ongoing portfolio cleanup, and a higher assumed future P/E multiple, even as revenue growth and profit margin assumptions are reset to more moderate levels.Analysartikel • Jun 17
Revvity (RVTY) Stock Could Be 10.9% Undervalued Despite Profit And Growth Pressure
Revvity (RVTY) is back in focus after recent commentary highlighted weak organic revenue growth, declining adjusted operating profits, and ongoing annual earnings per share pressure. These factors are sharpening questions about the stock’s core business performance. See our latest analysis for Revvity. At a share price of $101.22, Revvity’s recent 30-day share price return of 7.72% and 90-day gain of 19.18% suggest momentum has picked up, even though the 5-year total shareholder return is...Uppdatering av berättelse • Jun 15
RVTY: Elevated Multiple And China Exit Will Test 2026 Execution
Revvity's analyst fair value estimate has shifted from $95.00 to $90.00 as analysts factor in more measured assumptions for revenue growth, profit margins, and a higher future P/E, while also weighing recent price target moves and mixed ratings across the Street. Analyst Commentary Recent Street research on Revvity shows a mix of views, with several firms adjusting ratings and price targets in different directions.Uppdatering av berättelse • Jun 01
RVTY: Q1 Execution And Tools Demand Will Support Measured Future Earnings Power
Revvity's updated analyst price target has shifted to $113.64 from $119.56. This reflects a mix of recent target cuts and raises as analysts factor in revised growth and profitability assumptions, as well as a higher future P/E outlook.Analysartikel • May 08
Revvity, Inc. (NYSE:RVTY) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders of Revvity, Inc. ( NYSE:RVTY ) will be pleased this week, given that the stock price is up 14% to US$98.85...Uppdatering av berättelse • May 05
RVTY: Cautious 2026 Tools Recovery Setup Will Face Execution Debate
Revvity's updated analyst price target edges lower by $4 to reflect revised expectations following several price target cuts and a downgrade, partly offset by a recent upgrade from one research firm. Analyst Commentary Recent Street research on Revvity reflects a cautious tone, with several bearish analysts trimming price targets and reassessing expectations.Uppdatering av berättelse • Apr 21
RVTY: 2026 Tools Recovery Setup Will Face Mixed Execution Debate
The analyst fair value estimate for Revvity has been reset from $105 to $95, as analysts weigh recent target cuts alongside mixed rating changes and revised assumptions for growth, margins, and future P/E multiples. Analyst Commentary Recent Street research on Revvity has sent mixed signals, with several price target adjustments and at least one downgrade alongside an upgrade.Uppdatering av berättelse • Apr 06
RVTY: Recent Upgrade Cycle And Q4 Execution Will Drive Future Upside
Revvity's updated analyst price target edges up from $137.63 to $140.00 as analysts factor in a mix of recent target increases from several firms and a more cautious stance from at least one large bank. Analyst Commentary The latest Street research on Revvity reflects a split view, with several bullish analysts lifting price targets and one large bank taking a more cautious approach.Uppdatering av berättelse • Mar 23
RVTY: 2026 Tools Recovery Setup Will Support Healthier End Markets
Revvity’s analyst price targets have shifted higher by a few dollars across several firms, with analysts pointing to healthier end markets, improving procedure and CapEx trends into 2026, early recovery signs in China, and expectations for the company’s tools exposure as key supports for the updated valuations. Analyst Commentary Recent Street research on Revvity has centered on how much recovery in tools demand and procedure volumes is already reflected in current valuations.Uppdatering av berättelse • Mar 08
RVTY: 2026 Tools Demand And China Recovery Will Support Higher Earnings Power
Revvity's analyst price target edges higher from $114.63 to $119.56 as analysts factor in updated assumptions around discount rates, modestly slower revenue growth and slightly lower profit margins, along with a higher future P/E multiple supported by a series of recent target raises from Baird, TD Cowen, Evercore ISI, Barclays and Jefferies. Analyst Commentary Bullish analysts have been lifting their price targets in a fairly tight range, which points to a shared view that Revvity's risk or return profile has shifted enough to justify higher valuation assumptions, even as they factor in tempered expectations for revenue growth and margins.Uppdatering av berättelse • Feb 22
RVTY: Fair Value View Weighs 2026 Recovery Against Policy And China Risks
Analysts have nudged their targets on Revvity higher, with recent $3 to $6 price target increases clustered around a fresh $112 mark. They cite recovering end markets, healthier procedure and CapEx trends into 2026, and early signs of improvement in China as key supports for the updated view.Uppdatering av berättelse • Feb 08
RVTY: Fair Value View Balances Margin Upside With Policy And China Risks
Analysts have lifted their implied fair value for Revvity by $5 to $105, citing updated assumptions around profit margins, a lower future P/E multiple, and recent price target increases from several firms as key drivers of the recalibration. Analyst Commentary Recent Street research on Revvity has centered on fine tuning price targets and reassessing how much investors are willing to pay for the company, with several firms adjusting their models around margin expectations and appropriate P/E levels.Uppdatering av berättelse • Jan 25
RVTY: Q4 Margin Ramp And Sector Recovery Thesis Will Drive Upside
Narrative Update Analysts have lifted their price target on Revvity by about US$4 to reflect modestly higher fair value estimates and slightly stronger assumptions for revenue growth, Q4 execution and sector recovery potential into 2026. Analyst Commentary Bullish analysts are leaning constructive on Revvity, pointing to recent quarterly execution, updated guidance and sector trends as support for higher valuation ranges.Uppdatering av berättelse • Jan 11
RVTY: Q4 Margin Ramp And Buybacks Poised To Meet Cautious Recovery
The analyst price target for Revvity has been nudged higher by about $0.25, reflecting Street analysts' generally constructive view on recovering end markets, Q4 guidance that many see as achievable, and improving sector sentiment, even as some firm specific and China related risks remain in focus. Analyst Commentary Street research on Revvity is mixed but tilts constructive, with several firms nudging price targets higher while one new initiation takes a more cautious stance.Uppdatering av berättelse • Dec 27
RVTY: Q4 Margin Ramp And Buybacks Will Drive Next Phase
Analysts have nudged their average price target on Revvity modestly higher, reflecting confidence that Q4’s steeper ramp in sales and operating margins is achievable and supported by in-line Q3 organic growth, an earnings beat, and slightly improved forward earnings guidance, despite lingering company specific and macro headwinds. Analyst Commentary Bullish analysts highlight that Q3, while not spectacular, provides a solid springboard for a steeper ramp in Q4 sales and operating margins, which they view as achievable based on in line organic growth and an earnings beat.Analysartikel • Dec 18
Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Uppdatering av berättelse • Dec 13
RVTY Q4 Margin Ramp And Buybacks Will Drive Stronger Future Upside
Analysts have modestly raised their blended price target on Revvity to approximately $105 per share, up from around $100. This change reflects increased confidence that the company can deliver a steeper but achievable ramp in Q4 sales and margins while continuing to improve profitability, despite a slightly higher discount rate and lingering near term growth risks.Uppdatering av berättelse • Nov 29
RVTY: Buyback Program and Guidance Outlook Will Shape Next Phase
Analysts have increased their price target for Revvity to $105 from previous levels. They cite achievable Q4 guidance and an improved profit outlook, despite mixed quarterly results.Uppdatering av berättelse • Nov 15
RVTY: Recent Buyback Activity and Expanded Partnership Will Drive Near-Term Momentum
Revvity's analyst price target has increased from $99 to $105 per share, as analysts cite improving guidance for the upcoming quarter and stronger than expected recent performance, while noting that some risks remain. Analyst Commentary Analyst sentiment towards Revvity has shifted positively in recent weeks, reflecting improved financial guidance and resilient performance.Uppdatering av berättelse • Oct 31
RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead
Analysts have slightly raised their fair value estimate for Revvity by $1 to $113.67. They cite more achievable Q4 guidance and improved margin prospects following the company's recent earnings updates.Uppdatering av berättelse • Oct 17
Digital Transformation And Advanced Diagnostics Will Create Enduring Value
The consensus analyst price target for Revvity has decreased from $115.19 to $112.67. This change reflects lowered profit margin forecasts, slower revenue growth expectations, and continued market headwinds highlighted in recent research reports.Uppdatering av berättelse • Oct 03
Digital Transformation And Advanced Diagnostics Will Create Enduring Value
Analysts have slightly reduced their price target for Revvity by $1.63 to $115.19. They cite cautious optimism, as stable core markets are offset by ongoing sector uncertainties and revised forecasts for a slower recovery.Seeking Alpha • Feb 24
Revvity: Acquisitions In High-Growth Sectors, Excellent Debt Levels Create Notable Growth Potential
Summary Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position, reaching a 38.13% liabilities-to-assets ratio, the lowest value in eight years. In addition, it has improved its current ratio. Despite the fact that Revvity will face a weak demand in 2025, the two segments of Revvity expect a high growth rate in the long-term. Read the full article on Seeking AlphaAktieägarnas avkastning
| RVTY | US Life Sciences | US Marknad | |
|---|---|---|---|
| 7D | 17.7% | 4.3% | -1.6% |
| 1Y | 70.7% | 29.6% | 12.1% |
Avkastning vs industri: RVTY översteg US Life Sciences branschen som gav 29.6 % under det senaste året.
Avkastning vs Marknaden: RVTY översteg US marknaden som gav 12.1 % under det senaste året.
Prisvolatilitet
| RVTY volatility | |
|---|---|
| RVTY Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stabil aktiekurs: RVTY har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: RVTY s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1937 | 11,000 | Prahlad Singh | www.revvity.com |
Revvity, Inc. tillhandahåller lösningar, teknik och tjänster inom hälsovetenskap. Företaget erbjuder instrument, reagenser, mjukvara, abonnemang, detektions- och bildteknik, utökade garantier, utbildning och tjänster samt instrument, reagenser, analysplattformar och mjukvaruprodukter för tidig upptäckt av vanliga och sällsynta tillstånd, t.ex. graviditet och tidig barndom, samt testning av infektionssjukdomar på diagnostikmarknaden. Bolagets produkter används för testning och screening av genetiska avvikelser, störningar och sjukdomar, inklusive Downs syndrom, hypotyreos, muskeldystrofi, infertilitet och olika metaboliska tillstånd.
Revvity, Inc. Sammanfattning av grunderna
| RVTY grundläggande statistik | |
|---|---|
| Börsvärde | US$15.64b |
| Vinst(TTM) | US$237.37m |
| Intäkter(TTM) | US$2.91b |
68.5x
P/E-förhållande5.6x
P/S-förhållandeÄr RVTY övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| RVTY resultaträkning (TTM) | |
|---|---|
| Intäkter | US$2.91b |
| Kostnad för intäkter | US$1.31b |
| Bruttovinst | US$1.60b |
| Övriga kostnader | US$1.36b |
| Intäkter | US$237.37m |
Senast redovisade vinst
Jul 05, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 2.13 |
| Bruttomarginal | 54.98% |
| Nettovinstmarginal | 8.15% |
| Skuld/egenkapitalförhållande | 44.3% |
Hur har RVTY utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.2%
Aktuell utdelningsavkastning13%
UtbetalningskvotGer RVTY en tillförlitlig utdelning?
Se RVTY utdelningshistorik och jämförelsetal| Revvity datum för utdelning | |
|---|---|
| Ex utdelningsdag | Oct 23 2026 |
| Utbetalningsdag för utdelning | Nov 13 2026 |
| Dagar till Ex-utdelning | 36 days |
| Dagar till utdelningsdag | 57 days |
Ger RVTY en tillförlitlig utdelning?
Se RVTY utdelningshistorik och jämförelsetalFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/16 21:55 |
| Aktiekurs vid dagens slut | 2026/09/16 00:00 |
| Intäkter | 2026/07/05 |
| Årlig intjäning | 2025/12/28 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Revvity, Inc. bevakas av 40 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Luke Sergott | Barclays |